Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 25, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 950,000 Ordinary Shares of 25 pence each.
- Purchase Date: September 25, 2012.
- Price Range: Highest price paid was 1,461 pence per share; lowest price paid was 1,442.5 pence per share.
- Treasury Holdings (Settled): 495,565,427 shares (9.10% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,065,427 shares (10.09% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,948,029,435 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 950,000 shares for Treasury. This action increased the percentage of total voting rights held in Treasury from the prior settled position to 10.09% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (499,065,427 including unsettled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,948,029,435 shares in issue) for disclosure threshold assessments.
- Review the price paid (1,442.5 to 1,461 pence) against the market price on September 25, 2012, to assess execution efficiency.
- Note that this filing does not contain operational or financial performance data; refer to the most recent Form 20-F or interim results for those metrics.